PortalPublikationenThe course of cancer-related insomnia: don't expect it to di...

The course of cancer-related insomnia: don't expect it to disappear after cancer treatment

Standard

The course of cancer-related insomnia: don't expect it to disappear after cancer treatment. / Schieber, Katharina; Niecke, Alexander; Geiser, Franziska; Erim, Yesim; Bergelt, Corinna; Büttner-Teleaga, Antje; Maatouk, Imad; Stein, Barbara; Teufel, Martin; Wickert, Martin; Wuensch, Alexander; Weis, Joachim.

in: SLEEP MED, Jahrgang 58, 06.2019, S. 107-113.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schieber, K, Niecke, A, Geiser, F, Erim, Y, Bergelt, C, Büttner-Teleaga, A, Maatouk, I, Stein, B, Teufel, M, Wickert, M, Wuensch, A & Weis, J 2019, 'The course of cancer-related insomnia: don't expect it to disappear after cancer treatment', SLEEP MED, Jg. 58, S. 107-113. https://doi.org/10.1016/j.sleep.2019.02.018

APA

Schieber, K., Niecke, A., Geiser, F., Erim, Y., Bergelt, C., Büttner-Teleaga, A., Maatouk, I., Stein, B., Teufel, M., Wickert, M., Wuensch, A., & Weis, J. (2019). The course of cancer-related insomnia: don't expect it to disappear after cancer treatment. SLEEP MED, 58, 107-113. https://doi.org/10.1016/j.sleep.2019.02.018

Vancouver

Schieber K, Niecke A, Geiser F, Erim Y, Bergelt C, Büttner-Teleaga A et al. The course of cancer-related insomnia: don't expect it to disappear after cancer treatment. SLEEP MED. 2019 Jun;58:107-113. https://doi.org/10.1016/j.sleep.2019.02.018

Bibtex

@article{a8ff2a60b1d241b79e6259150b4f7f9c,
title = "The course of cancer-related insomnia: don't expect it to disappear after cancer treatment",
abstract = "OBJECTIVE: The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI.METHODS: This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2).RESULTS: In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in men insomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016).CONCLUSION: Insomnia is a common disorder in cancer patients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed.CLINICAL TRIAL REGISTRATION NUMBER: DRKS00004860.",
keywords = "Journal Article",
author = "Katharina Schieber and Alexander Niecke and Franziska Geiser and Yesim Erim and Corinna Bergelt and Antje B{\"u}ttner-Teleaga and Imad Maatouk and Barbara Stein and Martin Teufel and Martin Wickert and Alexander Wuensch and Joachim Weis",
note = "Copyright {\textcopyright} 2019 Elsevier B.V. All rights reserved.",
year = "2019",
month = jun,
doi = "10.1016/j.sleep.2019.02.018",
language = "English",
volume = "58",
pages = "107--113",
journal = "SLEEP MED",
issn = "1389-9457",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The course of cancer-related insomnia: don't expect it to disappear after cancer treatment

AU - Schieber, Katharina

AU - Niecke, Alexander

AU - Geiser, Franziska

AU - Erim, Yesim

AU - Bergelt, Corinna

AU - Büttner-Teleaga, Antje

AU - Maatouk, Imad

AU - Stein, Barbara

AU - Teufel, Martin

AU - Wickert, Martin

AU - Wuensch, Alexander

AU - Weis, Joachim

N1 - Copyright © 2019 Elsevier B.V. All rights reserved.

PY - 2019/6

Y1 - 2019/6

N2 - OBJECTIVE: The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI.METHODS: This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2).RESULTS: In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in men insomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016).CONCLUSION: Insomnia is a common disorder in cancer patients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed.CLINICAL TRIAL REGISTRATION NUMBER: DRKS00004860.

AB - OBJECTIVE: The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI.METHODS: This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2).RESULTS: In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in men insomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016).CONCLUSION: Insomnia is a common disorder in cancer patients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed.CLINICAL TRIAL REGISTRATION NUMBER: DRKS00004860.

KW - Journal Article

U2 - 10.1016/j.sleep.2019.02.018

DO - 10.1016/j.sleep.2019.02.018

M3 - SCORING: Journal article

C2 - 31146122

VL - 58

SP - 107

EP - 113

JO - SLEEP MED

JF - SLEEP MED

SN - 1389-9457

ER -